The Centers for Medicare & Medicaid Services has identified Healthcare Common Procedure Coding System codes for billing Medicare for the combination monoclonal antibodies bamlanivimab and etesevimab, made by Eli Lilly and Co.

The Food and Drug Administration this month authorized administering the monoclonal antibodies together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy. The emergency use authorization also authorizes the treatment for patients 65 or older with certain chronic medical conditions.

Related News Articles

Blog
America’s hospitals and health systems, and our heroic caregivers, have been on the front lines of the battle against COVID-19 for the past year, working…
Headline
The AHA today urged the Centers for Medicare & Medicaid Services to use its oversight authority for Medicare Advantage, Medicaid managed care, Children’s…
Headline
The AHA today voiced support for the Medicare Sequester COVID Moratorium Act (H.R. 315), legislation that would eliminate Medicare sequester cuts during the…
Headline
AHA today urged the Centers for Medicare & Medicaid Services to immediately withdraw its Most Favored Nation model interim final rule and “replace it with…
Headline
The Centers for Medicare & Medicaid Services yesterday released a request for applications to participate in the Part D Payment Modernization Model in…
Headline
Only 132 of the 334 off-campus provider-based hospital outpatient departments that requested a “mid-build” exception for Medicare to continue to pay them under…